Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Astellas Discontinues ASP8273 Treatment and Closes Randomization for Clinical Study Protocol 8273-CL

americanpharmaceuticalreviewMay 12, 2017

Tag: Astellas Pharma , NSCLC

PharmaSources Customer Service